Adenoviral Vector-mediated Gene Therapy for Gliomas: Coming of Age

Overview

Journal Expert Opin Biol Ther

Specialties Biology
Pharmacology

Date 2014 Apr 30

PMID 24773178

Citations 28

Authors

Maria G Castro

Marianela Candolfi

Thomas J Wilson

Alexandra Calinescu

Christopher Paran

Neha Kamran

Carl Koschmann

Mariela A Moreno-Ayala

Hikmat Assi

Pedro R Lowenstein

Affiliations

Soon will be listed here.

Abstract

Introduction: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and it carries a dismal prognosis. Adenoviral vector (Ad)-mediated gene transfer is being developed as a promising therapeutic strategy for GBM. Preclinical studies have demonstrated safety and efficacy of adenovirus administration into the brain and tumor mass in rodents and into the non-human primates' brain. Importantly, Ads have been safely administered within the tumor resection cavity in humans.

Areas Covered: This review gives background on GBM and Ads; we describe gene therapy strategies for GBM and discuss the value of combination approaches. Finally, we discuss the results of the human clinical trials for GBM that have used Ads.

Expert Opinion: The transduction characteristics of Ads, and their safety profile, added to their capacity to achieve high levels of transgene expression have made them powerful vectors for the treatment of GBM. Recent gene therapy successes in the treatment of retinal diseases and systemic brain metabolic diseases encourage the development of gene therapy for malignant glioma. Exciting clinical trials are currently recruiting patients; although, it is the large randomized Phase III controlled clinical trials that will provide the final decision on the success of gene therapy for the treatment of GBM.

Citing Articles

The tumor micro-environment in pediatric glioma: friend or foe?.

Messiaen J, Jacobs S, De Smet F Front Immunol. 2023; 14:1227126.

PMID: 37901250 PMC: 10611473. DOI: 10.3389/fimmu.2023.1227126.

Evaluation of Baculoviruses as Gene Therapy Vectors for Brain Cancer.

Garcia Fallit M, Pidre M, Asad A, Pena Agudelo J, Vera M, Nicola Candia A Viruses. 2023; 15(3).

PMID: 36992317 PMC: 10051617. DOI: 10.3390/v15030608.

Advances in immunotherapy for glioblastoma multiforme.

Mahmoud A, Ajina R, Aref S, Darwish M, Alsayb M, Taher M Front Immunol. 2022; 13:944452.

PMID: 36311781 PMC: 9597698. DOI: 10.3389/fimmu.2022.944452.

Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment.

Franson A, McClellan B, Varela M, Comba A, Syed M, Banerjee K Front Med (Lausanne). 2022; 9:966458.

PMID: 36186781 PMC: 9515652. DOI: 10.3389/fmed.2022.966458.

Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms.

Karami Fath M, Babakhaniyan K, Anjomrooz M, Jalalifar M, Alizadeh S, Pourghasem Z Vaccines (Basel). 2022; 10(9).

PMID: 36146527 PMC: 9501259. DOI: 10.3390/vaccines10091448.

References

Dachs G, Tupper J, Tozer G . From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs. 2005; 16(4):349-59. DOI: 10.1097/00001813-200504000-00001. View

MAHALEY Jr M, Brooks W, Roszman T, Bigner D, Dudka L, Richardson S . Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. J Neurosurg. 1977; 46(4):467-76. DOI: 10.3171/jns.1977.46.4.0467. View

Lowenstein P, Castro M . Genetic engineering within the adult brain: implications for molecular approaches to behavioral neuroscience. Physiol Behav. 2001; 73(5):833-9. DOI: 10.1016/s0031-9384(01)00520-0. View

Street S, Cretney E, Smyth M . Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood. 2001; 97(1):192-7. DOI: 10.1182/blood.v97.1.192. View

Smith J, Raper S, Wheeldon E, Hackney D, Judy K, Wilson J . Intracranial administration of adenovirus expressing HSV-TK in combination with ganciclovir produces a dose-dependent, self-limiting inflammatory response. Hum Gene Ther. 1997; 8(8):943-54. DOI: 10.1089/hum.1997.8.8-943. View

CHAKRAVARTY P, Alfieri A, Thomas E, Beri V, Tanaka K, Vikram B . Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res. 2000; 59(24):6028-32. View

Keyvani K, Baur I, Paulus W . Tetracycline-controlled expression but not toxicity of an attenuated diphtheria toxin mutant. Life Sci. 1999; 64(19):1719-24. DOI: 10.1016/s0024-3205(99)00109-5. View

Curtin J, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K . HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009; 6(1):e10. PMC: 2621261. DOI: 10.1371/journal.pmed.1000010. View

Chiocca E, Abbed K, Tatter S, Louis D, Hochberg F, Barker F . A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther. 2004; 10(5):958-66. DOI: 10.1016/j.ymthe.2004.07.021. View

10.

Graham F, Van Der Eb A . A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973; 52(2):456-67. DOI: 10.1016/0042-6822(73)90341-3. View

11.

Kaplan D, Shankaran V, Dighe A, STOCKERT E, Aguet M, Old L . Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998; 95(13):7556-61. PMC: 22681. DOI: 10.1073/pnas.95.13.7556. View

12.

Hamed H, Yacoub A, Park M, Eulitt P, Dash R, Sarkar D . Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther. 2010; 18(6):1130-1142. PMC: 2889737. DOI: 10.1038/mt.2010.29. View

13.

Curtin J, Candolfi M, Xiong W, Lowenstein P, Castro M . Turning the gene tap off; implications of regulating gene expression for cancer therapeutics. Mol Cancer Ther. 2008; 7(3):439-48. PMC: 2593107. DOI: 10.1158/1535-7163.MCT-07-2328. View

14.

VanderVeen N, Paran C, Krasinkiewicz J, Zhao L, Palmer D, Hervey-Jumper S . Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma. Hum Gene Ther Clin Dev. 2013; 24(3):116-26. PMC: 4003468. DOI: 10.1089/humc.2013.139. View

15.

Moolten F . Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986; 46(10):5276-81. View

16.

Chiocca E, Aguilar L, Bell S, Kaur B, Hardcastle J, Cavaliere R . Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol. 2011; 29(27):3611-9. PMC: 3179270. DOI: 10.1200/JCO.2011.35.5222. View

17.

King G, Muhammad A, Curtin J, Barcia C, Puntel M, Liu C . Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol. 2007; 10(1):19-31. PMC: 2600834. DOI: 10.1215/15228517-2007-045. View

18.

Muhammad A, Candolfi M, King G, Yagiz K, Foulad D, Mineharu Y . Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res. 2009; 15(19):6113-27. PMC: 2796687. DOI: 10.1158/1078-0432.CCR-09-1087. View

19.

Lowenstein P . Dendritic cells and immune responses in the central nervous system. Trends Immunol. 2002; 23(2):70. DOI: 10.1016/s1471-4906(01)02151-2. View

20.

Valerie K, Brust D, FARNSWORTH J, Amir C, Taher M, HERSHEY C . Improved radiosensitization of rat glioma cells with adenovirus-expressed mutant herpes simplex virus-thymidine kinase in combination with acyclovir. Cancer Gene Ther. 2000; 7(6):879-84. DOI: 10.1038/sj.cgt.7700185. View